tetano
Editor, Senior Moderator
Clin Rheumatol
. 2022 Feb 19.
doi: 10.1007/s10067-022-06106-1. Online ahead of print.
Flare of adult-onset Still's disease following mRNA COVID-19 vaccination: a case report and review of literature
Ji-Won Kim[SUP] 1 [/SUP], Ju-Yang Jung[SUP] 1 [/SUP], Chang-Hee Suh[SUP] 1 [/SUP], Hyoun-Ah Kim[SUP] 2 [/SUP]
Affiliations
Abstract
The upheaval caused by the coronavirus disease 2019 (COVID-19) pandemic has allowed to large population to use new vaccines urgently. Although vaccine development programs and available epidemiological data reassure us, there are concerns about specific risks associated with vaccinations in patients with autoimmune-autoinflammatory diseases. These patients have the potential to decrease humoral and cellular immune responses caused by biologic agents and develop an acute flare of underlying disease following vaccination. We herein present a rare case of a 49-year-old female with a flare of adult-onset Still's disease (AOSD) after the first dose of BNT162b2 mRNA COVID-19 vaccination. She had been diagnosed with AOSD 7 years earlier and had achieved remission with tocilizumab. This patient came to the emergency room with fever and nausea that occurred 4 days after the first vaccination. Based on laboratory results and clinical manifestations, we suspected AOSD flare and was treated with steroid pulse therapy. In this report, we also discuss possible mechanisms linking vaccination with a flare of AOSD. Considering the close time relationship between COVID-19 vaccinations and a flare of AOSD, physicians should be aware of adverse events from this new vaccination and evaluate the benefits and risks of vaccination for each patient. KEY POINTS: • COVID-19 vaccination may cause an AOSD flare in patients who are in remission with tocilizumab.
Keywords: Adult-onset Still’s disease; Biologic agent; COVID-19 vaccination; Disease activity; Flare.
. 2022 Feb 19.
doi: 10.1007/s10067-022-06106-1. Online ahead of print.
Flare of adult-onset Still's disease following mRNA COVID-19 vaccination: a case report and review of literature
Ji-Won Kim[SUP] 1 [/SUP], Ju-Yang Jung[SUP] 1 [/SUP], Chang-Hee Suh[SUP] 1 [/SUP], Hyoun-Ah Kim[SUP] 2 [/SUP]
Affiliations
- PMID: 35182269
- DOI: 10.1007/s10067-022-06106-1
Abstract
The upheaval caused by the coronavirus disease 2019 (COVID-19) pandemic has allowed to large population to use new vaccines urgently. Although vaccine development programs and available epidemiological data reassure us, there are concerns about specific risks associated with vaccinations in patients with autoimmune-autoinflammatory diseases. These patients have the potential to decrease humoral and cellular immune responses caused by biologic agents and develop an acute flare of underlying disease following vaccination. We herein present a rare case of a 49-year-old female with a flare of adult-onset Still's disease (AOSD) after the first dose of BNT162b2 mRNA COVID-19 vaccination. She had been diagnosed with AOSD 7 years earlier and had achieved remission with tocilizumab. This patient came to the emergency room with fever and nausea that occurred 4 days after the first vaccination. Based on laboratory results and clinical manifestations, we suspected AOSD flare and was treated with steroid pulse therapy. In this report, we also discuss possible mechanisms linking vaccination with a flare of AOSD. Considering the close time relationship between COVID-19 vaccinations and a flare of AOSD, physicians should be aware of adverse events from this new vaccination and evaluate the benefits and risks of vaccination for each patient. KEY POINTS: • COVID-19 vaccination may cause an AOSD flare in patients who are in remission with tocilizumab.
Keywords: Adult-onset Still’s disease; Biologic agent; COVID-19 vaccination; Disease activity; Flare.